## ILMN: Illumina, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.62 indicates fundamental undervaluation. Quality metrics strong (ROE 31%). Consistent execution (3/4 quarters beat estimates). Caution: momentum weakening (-1.7% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($119.25)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Illumina at the 2025 China International Import Expo (CIIE)**
- Source: Illumina | 20251206T040238 | Bullish | Relevance: 98%
- Illumina showcased new technologies and formed partnerships at the 2025 China International Import Expo (CIIE), demonstrating its commitment to China's "In China, For China" strategy. The company is a global genomics leader, providing comprehensive next-generation sequencing solutions across various research, clinical, and applied markets. Illumina's innovative sequencing and array technologies are driving advancements in life science research, translational and consumer genomics, and molecular diagnostics.

**2. Precision oncology at your communityâ€™s doorstep**
- Source: Illumina | 20251208T151032 | Bullish | Relevance: 97%
-  Illumina is making comprehensive genomic profiling (CGP) testing more accessible to community cancer care centers. This allows in-house labs to utilize CGP, which assesses hundreds of genes and biomarkers, to improve therapeutic options and patient outcomes. The move aims to decentralize CGP testing, reducing turnaround times and operational barriers for local oncology practices.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.09M) |
| Sells | 8 ($80.27M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 53.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Capital World Invest: 13.1% (+20.0%)
- Blackrock Inc.: 12.2% (-3.5%)
- Vanguard Group Inc: 9.6% (-3.5%)
- State Street Corpora: 3.9% (+6.8%)
- Sessa Capital IM, L.: 3.1% (-0.8%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-1.7% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $80M sold (8 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.62 indicates undervaluation relative to growth. Forward P/E 25.4x stretched relative to 6% growth. Quality metrics strong (ROE 31%, margin 16%). Insider selling cluster ($80.3M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $19.6B |
| Beta | 1.44 |
| 52W Range | $68.70 - $153.06 |
| Short Interest | 6.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.62 |
| Forward P/E | 25.4 |
| Current P/E | 27.0 |
| YoY Growth | 6.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 1.6% to -0.1% (-1.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.1pp (needs >4.0% for momentum thesis). Outperforming sector by 3.2pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-0.60), momentum weakening.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.14% (CS: 56) | Neutral |
| RSI_14 | 61.5 | Neutral |
| MACD Histogram | -0.60 | Bearish |
| vs SMA20 | 1.019x | Above |
| vs SMA50 | 1.145x | Above |
| vs SMA200 | 1.340x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $127.25
- **Stop Loss:** $119.25 (6.3% risk)
- **Target:** $143.25 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 62
- **Position Value:** $7,889.50
- **Portfolio %:** 7.89%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-05 (Est: $1.23)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.17 | $1.34 | +14.7% |
| 2025Q2 | $1.01 | $1.19 | +17.7% |
| 2025Q1 | $0.94 | $0.97 | +3.3% |
| 2024Q4 | $0.92 | $0.86 | -6.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*